Taro Pharmaceutical Industries Ltd
TARO67
$42.970.00%$0.00
TARO67
$42.97
0.00%Performance History
| Key Stats | |
|---|---|
| Open | $42.97 |
| Prev. Close | $42.97 |
| EPS | 1.43 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 42.89 | 42.98 |
| 52 Week Range | 32.67 | 45.76 |
| Ratios | |
|---|---|
| EPS | 1.43 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Taro Pharmaceutical Industries Ltd (TARO)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. Uday V. Baldota
- Headquarters
- Haifa
- Employees
- 1554
- Exchange
- NYSE
Keep an eye on Taro Pharmaceutical Industries Ltd
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Taro Pharmaceutical Industries Ltd's (TARO) price per share?
The current price per share for Taro Pharmaceutical Industries Ltd (TARO) is $42.97. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Taro Pharmaceutical Industries Ltd (TARO)?
For Taro Pharmaceutical Industries Ltd (TARO), the 52-week high is $45.76, which is 6.49% from the current price. The 52-week low is $32.67, the current price is 31.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Taro Pharmaceutical Industries Ltd (TARO) a growth stock?
Taro Pharmaceutical Industries Ltd (TARO) has shown an average price growth of 0.41% over the past three years. It has received a score of 47 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Taro Pharmaceutical Industries Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Taro Pharmaceutical Industries Ltd (TARO) stock price performance year to date (YTD)?
As of the latest data, Taro Pharmaceutical Industries Ltd (TARO) has a year-to-date price change of 2.9%. Over the past six months, the figure is 2.09%. Looking at a longer horizon, the five-year price change stands at -45.99%.
help
Is Taro Pharmaceutical Industries Ltd (TARO) a profitable company?
Taro Pharmaceutical Industries Ltd (TARO) has a net income of $53.87M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.47% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 5.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $629.18M, with a revenue growth rate of 9.81%, providing insight into the company's sales performance and growth. The gross profit is $304.98M. Operating income is noted at $21.51M. Furthermore, the EBITDA is $74.41M.
help
What is the market capitalization of Taro Pharmaceutical Industries Ltd (TARO)?
Taro Pharmaceutical Industries Ltd (TARO) has a market capitalization of $1.62B. The average daily trading volume is 85.28K, indicating the stock's liquidity and investor engagement.
News
12/29/2023
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
12/28/2023
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
12/27/2023
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
12/26/2023
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
12/26/2023
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
12/22/2023
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program